secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K/A
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001420720-22-000091
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Thomas Isett resigns effective immediately; interim office of CEO established
--------------------------------------------------------------------------------

- Thomas F. Isett resigned as CEO and Board member effective December 1, 2022, with employment ending December 31, 2022.
- Severance includes 24-month base salary, pro rata target bonus, 24-month target bonus, and up to 18 months COBRA subsidy.
- Robert Lutz (CFO) and Martin Brenner (CSO) will fill the office of the CEO during the search; leadership reports to Chair William Clark.
- Departure was not due to any disagreement with the Company's strategy, operations, or accounting policies.
- Isett will assist with sale of CDMO assets through March 2023 and litigation matters through December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072022000091/0001420720-22-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072022000091/ibio-20221201x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001420720-22-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer